ALS Therapy Development Institute created PRISM ALS to develop patient-derived motor neuron models representing sporadic ALS and benchmark them against familial ALS lines.

The ALS Therapy Development Institute (ALS TDI) and its researchers discover and develop potential treatments for ALS. It is the world’s first and largest nonprofit biotech focused 100 percent on ALS research. Led by drug development experts and people living with ALS, ALS TDI understands the urgent need to slow and stop this disease. Based in the Greater Boston Area, ALS TDI has over 30 full-time, industry trained, drug development experts on staff. ALS TDI is internationally recognized as a leader in preclinical and translational ALS research, and partners with pharmaceutical companies and biotechs around the world. Rated a four-star nonprofit on Charity Navigator, ALS TDI spends 87 cents of every dollar raised on research to find an effective treatment and cure. Learn more at www.als.net.